Shakhnovich V, et al. - Researchers conducted a prospective pharmacokinetics (PK) investigation of pantoprazole in obese children to evaluate appropriate pantoprazole dosing for obese children. As per the outcomes, lean body weight dosing of pantoprazole led to pantoprazole PK similar to nonobese peers. Additional factors [other than body size (eg, age-related changes in CYP2C19 activity)] seemed to affect pantoprazole PK in children <12 years of age.